AR041735A1 - Compuestos de amida con accion antagonista de mch y medicamentos que contienen estos compuestos - Google Patents

Compuestos de amida con accion antagonista de mch y medicamentos que contienen estos compuestos

Info

Publication number
AR041735A1
AR041735A1 ARP030103995A ARP030103995A AR041735A1 AR 041735 A1 AR041735 A1 AR 041735A1 AR P030103995 A ARP030103995 A AR P030103995A AR P030103995 A ARP030103995 A AR P030103995A AR 041735 A1 AR041735 A1 AR 041735A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
carbonyl
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP030103995A
Other languages
English (en)
Inventor
Dirk Stenkamp
Thorsten Lehmann-Lintz
Rudolf Klaus Dr
Lustenberger Philipp Dr
Ralf R H Lotz
Martin Lenter
Stephane Roth
Kirsten Arndt
Heike-Andrea Wieland
Stephan Georg Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR041735A1 publication Critical patent/AR041735A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a compuestos de amida de fórmula general (1) en la cual R1, R2, de manera independiente entre sí, significan H, un grupo alquilo C1-8 o cicloalquilo C3-7 eventualmente sustituido con el radical R11, pudiendo un grupo -CH2- en la posición 3 o 4 de un grupo cicloalquilo de 5, 6 o 7 eslabones, haber sido reemplazados por -O-, -S- o -NR13-, o bien un radical fenilo o piridinilo eventualmente sustituido una o varias veces con el radical R12 y/o sustituido una vez con nitro, o bien R1 y R2 forman un puente alquileno C2-8, en el cual uno o dos grupos -CH2- de manera independiente entre sí, pueden haber sido reemplazados por -CH=N- o -CH=CH- y/o uno o dos grupo -CH2-, de manera independiente entre sí, pueden haber sido reemplazados por -O-; -S-; -SO;-(SO2)-, -C=N-O-R18, -CO-, -C(=CH2)- o -NR13- de manera tal que los heteroátomos no estén pudiendo haber sido reemplazados, en el puente de alquileno antes definido, uno o varios átomos de H por R14, y pudiendo estar sustituido el puente de alquileno antes definido con uno o dos grupos carbo- o heterocíclicos Cy, iguales o diferentes de manera tal que la unión entre el puente alquileno y el grupo Cy tiene lugar a través de un enlace sencillo o doble; a través de un átomo de C común, con formación de un sistema anular espirocíclico; a través de dos átomos de C y/o de N comunes, contiguos, con formación de un sistema anular bicíclico condensado, o bien a través de tres o más átomos de C y/ o N, con formación de un sistema anular punteado; R3 significa H, alquilo C1-6, cicloalquilo C3-7 o (cicloalquil C3-7)-(alquilo C1-4); X significa un puente de alquileno C1-8, en el cual un grupo -CH2- puede haber sido reemplazado por -CH=CH- o -C:::C- y/o uno o dos grupos -CH2-, de manera independiente entre sí, pueden haber sido reemplazados por -O-; -S-; -(SO)-; -(SO2)-;-CO- o -NR4- de manera tal que en cada caso no estén unidos directamente entre sí dos átomos de O, de S o de N, o bien un átomo de O con un átomo de S, pudiendo estar unido el puente X a R1, incluyendo el átomo de N unido a R1 y a X, con formación de un grupo heterocíclico, pudiendo estar unido adicionalmente el puente X también a R2, incluyendo el átomo de N unido a R2 y a X, y con formación de un grupo heterocíclico, y pudiendo estar unidos entre sí dos átomos de C o bien un átomo de C y un átomo de N del puente de alquileno a través de un puente de alquileno C1-4 adicional, y pudiendo estar sustituido un átomo de C con R10 y/ o uno o dos átomos de C en cada caso, con uno o dos sustituyentes, iguales o diferentes, seleccionados de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, (cicloalquil C3-7)-(alquilo C1-3), cicloalquenilo C4-7 y (cicloalquenil C4-7)-(alquilo C1-3), pudiendo estar unidos entre sí dos sustituyentes alquilo y/o alquenilo, con formación de un sistema anular carbocíclico, y W está seleccionado del grupo compuesto por -CR6aR6b-O-, -CR7a=CR7c-, -CR6aR6b-NR8-, -CR7aR7b-CR7cR7d- y -NR8-CR6aR6b-; Z significa un enlace sencillo, alquileno C1-4, en donde dos átomos de C contiguos pueden estar unidos entre sí con un puente alquileno C1-4 adicional, pudiendo un átomo de C del puente de alquileno estar sustituido con R10 y/o uno o dos átomos de C, de manera independiente entre sí, estar sustituidos con uno o dos radicales alquilo C1-6, iguales o diferentes, pudiendo estar unidos entre si dos radicales alquilo, con formación de un anillo carbocíclico, e Y tiene uno de los significados indicados para Cy, pudiendo estar unido R1 a Y, con inclusión del grupo X y del átomo de N unido a R1 y a X, y con formación de un grupo heterocíclico condensado a Y, y/o pudiendo estar unido X a Y, con formación de un grupo carbo- o heterocíclico condensado a Y, y A tiene uno de los significados indicados para Cy; B tiene uno de los significados indicados para Cy, b tiene el valor 0 o 1; Cy significa un grupo carbo- o heterocíclico seleccionado de uno de los siguientes significados: un grupo carbocíclico saturado de 3 a 7 eslabones, un grupo carbocíclico insaturado de 4 a 7 eslabones, un grupo fenilo, un grupo heterocíclico saturado de 4 a 7 eslabones o insaturado de 5 a 7 eslabones con un átomo de N, de O o de S como heteroátomo, un grupo heterocíclico saturado o insaturado de 5 a 7 eslabones con dos o más átomos de N o con uno o dos átomos de N y un átomo de O o de S como heteroátomos, un grupo heterocíclico aromático de 5 o 6 eslabones con uno o varios heteroátomos iguales o diferentes seleccionados de N, O y/o S, pudiendo los grupos de 4, 5, 6 o 7 eslabones antes indicados estar unidos de manera condensada con un anillo de fenilo o con un anillo de piridina, a través de dos átomos de C comunes contiguos, y pudiendo en los grupos de 5, 6 o 7 eslabones antes mencionados haber sido reemplazados uno o dos grupos -CH2- no contiguos, de manera independiente entre si, por un grupo -CO-, -C(=CH2)-, -(SO)- o -(SO2)-, y pudiendo los grupos saturados de 6 o 7 eslabones antes indicados presentarse también como sistemas anulares punteados con un puente imino, N-(alquil C1-4)-imino, metileno, (alquil C1-4)-metileno o di(alquil C1-4)-metileno y pudiendo estar los grupos cíclicos antes mencionados sustituidos una o varias veces en uno o varios átomos de C con R20, en el caso de un grupo fenilo, también adicionalmente una vez con nitro, y/o uno o varios grupos NH con R21; R4 tiene uno de los significados indicados para R17, alquenilo C2-6 o alquinilo C3-6;R6a y R6b significan H, alquilo C1-4 o CF3, R7a, R7b; R7c, R7d significan H, F, alquilo C1-4 o CF3; R8 significa H, alquilo C1-4, cicloalquilo C3-7 o (cicloalquil C3-7)-(alquilo C1-3); R10 significa hidroxi, omega-hidroxi-(alquilo C1-3), alcoxi C1-4, omega-(alcoxi C1-4)-(alquilo C1-3), carboxi, (alcoxi C1-4)-carbonilo, amino, (alquil C1-4)-amino, di-(alquil C1-4)-amino, (cicloalquilenimino C3-6)imino, amino-(alquilo C1-3), (alquil C1-4)--amino-alquilo (C1-3), di-(alquil C1-4)-amino-(alquilo C1-3), (cicloalquilen C3-6)--imino-(alquilo C1-3), amino-(alcoxi C1-3), (alquil C1-4)-amino-(alcoxi C1-3), di-(alquil C1-4)-amino-(alcoxi C1-3), o bien (cicloalquilen C3-6)-imino-(alcoxi C1-3), aminocarbonilo, (alquil C1-4)-aminocarbonilo, di-(alquil C1-4)-amino-carbonilo o (cicloalquilen C3-6)-imino-carbonilo; R11 significa alquenilo C2-6, alquinilo C2-6, -R15-O-, -R15-O-CO-, R15-CO-O-, R16R17N-, R18R19N-CO- o Cy-; R12 tiene uno de los significados indicados para R20; R13 tiene uno de los significados indicados para R 17, salvo carboxi; R14 significa halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, R15-O-, -R15-O-CO-, -R15-CO-, R15-CO-O-, -R16R17N-, R18R19N-CO, R15-O-(alquilo C1-3), R15-O-CO-(alquilo C1-3), R15-O-CO-NH-, R15-SO2-NH-, R15-CO-(alquilo C1-3), R15-CO-O-(alquilo C1-3), R1617N-(alquilo C1-3), R18R19N-CO-(alquilo C1-3) o Cy-(alquilo C1-3); R15 significa H, alquilo C1-4, cicloalquilo C3-7, (cicloalquil C3-7)-(alquilo C1-3), fenilo, fenil-(alquilo C1-3), piridinilo o piridinil-(alquilo C1-3); R16 es H, alquilo C1-6, cicloalquilo C3-7, (cicloalquil C3-7)-(alquilo C1-3), cicloalquenilo C4-7, (cicloalquenil C4-7)-(alquilo C1-3), omega-hidroxi-(alquilo C2-3), omega-(alcoxi C1-4)-(alquilo C2-3), amino-(alquilo C2-6), (alquil C1-4)-amino-(alquilo C2-6), di-(alquil C1-4)-amino-(alquilo C2-6) o (cicloalquilen C3-6)-imino-(alquilo C2-6); R17 tiene uno de los significados indicados para 16 o bien fenilo, fenil-(alquilo C1-3), piridinilo, dioxolan-2-ilo, -CHO, (alquil C1-4)-carbonilo, carboxi, hidroxicarbonil-(alquilo C1-3), (alcoxi C1-4)-carbonilo, (alcoxi C1-4)-carbonil-(alquilo C1-3), (alquil C1-4)-carbonilamino-(alquilo C2-3), N-((alquil C1-4)-carbonil)-N-(alquil C1-4)-amino-(alquilo C2-3), (alquil C1-4)-sulfonilo, (alquil C1-4)-sulfonilamino-(alquilo C2-3) o N-((alquil C1-4)-sulfonil)--N-(alquil C1-4)-amino-(alquilo C2-3); R18, R19 de manera independiente entre sí, significan H o alquilo C1-6; R20 significa halógeno, hidroxi, ciano, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, (cicloalquil C3-7)-(alquilo C1-3), hidroxi-(alquilo C1-3), R22-(alquilo C1-3) o bien uno de los significados indicados para R22; R21 significa alquilo C1-4, omega-hidroxi-(alquilo C2-3), omega-(alcoxi C1-4)-(alquilo C2-6), omega-(alquil C1-4)-amino-(alquilo C2-6), omega-di-(alquil C1-4)-amino-(alquilo C2-6), omega-(cicloalquilen C3-6)-imino-(alquilo C2-6), fenil-(alquilo C1-3), (alquil C1-4)--carbonilo, (alcoxi C1-4)-carbonilo, o (alquil C1-4)-sulfonilo; R22 significa fenil-(alcoxi C1-3), -OHC, -HO-N=HC, (alcoxi C1-4)-N=HC-, alcoxi C1-4, (alquil C1-4)tio, carboxi, (alquil C1-4)-carbonilo, (alcoxi C1-4)-carbonilo, aminocarbonilo, (alquil c1-4)-aminocarbonilo, di-(alquil C1-4)-aminocarbonilo, (cicloalquil C3-6)-amino-carbonilo, (ciclo-alquilen C3-6)-imino-carbonilo, (cicloalquilen C3-6)-imino-(alquil-C2-4)-amino-carbonilo, fenil-aminocarbonilo, (alquil C1-4)-sulfonilo, (alquil C1-4)-sulfinilo, (alquil C1-4)-sulfonilamino, amino, (alquil C1-4)-amino, di-(alquil C1-4)-amino, (alquil C1-4)-carbonil-amino, (cicloalquilen C3-6)-imino, fenil-/alquil C1-3)-amino, o bien N-(alquil C1-4)-fenil-(alquil C1-3)-amino, acetilamino, propionilamino, fenilcarbonilamino, fenilcarbonilmetilamino, hidroxialquilaminocarbonilo, (4-morfolinil)carbonilo, (1-pirrolidinil)carbonilo, (1-piperidinil)carbonilo, (hexahidro-1-azepinil)carbonilo, (4-metil-1-piperazinil)carbonilo, metilendioxi, aminocarbonilamino o alquilaminocarbonilamino, pudiendo, en los grupos y radicales antes mencionados, en especial en A, B, W, X, Y, Z, R1 hasta R4, R6a, R6b, R7a, R7b, R7c, R7d, R8 y R10 hasta R22, estar sustituidos en cada caso uno o varios átomos de C, de manera adicional, una o varias veces con F y/o en cada caso estar sustituidos uno o dos átomos de C de manera independiente entre sí, adicionalmente, y una sola vez, con Cl, o Br y/o en cada caso uno o varios anillo de fenilo, de manera independiente entre sí, y adicionalmente, con uno, dos o tres sustituyentes seleccionados del grupo de F, Cl, Br, I, alqu
ARP030103995A 2002-10-31 2003-10-31 Compuestos de amida con accion antagonista de mch y medicamentos que contienen estos compuestos Suspension/Interruption AR041735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10250743A DE10250743A1 (de) 2002-10-31 2002-10-31 Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
AR041735A1 true AR041735A1 (es) 2005-05-26

Family

ID=32115015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103995A Suspension/Interruption AR041735A1 (es) 2002-10-31 2003-10-31 Compuestos de amida con accion antagonista de mch y medicamentos que contienen estos compuestos

Country Status (24)

Country Link
EP (1) EP1558567B1 (es)
JP (1) JP2006504761A (es)
KR (1) KR20050065654A (es)
CN (1) CN1708476A (es)
AR (1) AR041735A1 (es)
AT (1) ATE434601T1 (es)
AU (1) AU2003285306A1 (es)
BR (1) BR0315797A (es)
CA (1) CA2504207C (es)
CO (1) CO5570698A2 (es)
DE (2) DE10250743A1 (es)
EA (1) EA009040B1 (es)
EC (1) ECSP055765A (es)
ES (1) ES2327329T3 (es)
HR (1) HRP20050383A2 (es)
MX (1) MXPA05002865A (es)
NO (1) NO20050745L (es)
PE (1) PE20040785A1 (es)
PL (1) PL376256A1 (es)
RS (1) RS20050330A (es)
TW (1) TW200412936A (es)
UY (1) UY28051A1 (es)
WO (1) WO2004039764A1 (es)
ZA (1) ZA200501164B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
FR2866880A1 (fr) * 2004-02-27 2005-09-02 Oreal Para-phenylenediamine secondaire n-alkylaminee ortho-et/ou meta-substituee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
JP2006076990A (ja) * 2004-03-12 2006-03-23 Bayer Cropscience Ag 殺虫性ベンゼンジカルボキサミド類
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2008022979A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
WO2008069611A1 (en) * 2006-12-08 2008-06-12 Korea Research Institute Of Chemical Technology N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same
CL2007003580A1 (es) 2006-12-11 2009-03-27 Boehringer Ingelheim Int Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
AR073049A1 (es) * 2008-08-07 2010-10-13 Bayer Cropscience Sa Derivados fungicidas de oxialquilamida
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012008549A1 (ja) 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RS56823B1 (sr) 2011-07-29 2018-04-30 Karyopharm Therapeutics Inc Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe
SG10201609097PA (en) * 2011-07-29 2016-12-29 Karyopharm Therapeutics Inc Nuclear transport modulators and uses thereof
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
US9096543B2 (en) 2012-05-09 2015-08-04 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10221138B2 (en) 2013-06-27 2019-03-05 Lg Chem, Ltd. Biaryl derivatives as GPR120 agonists
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EA201790384A1 (ru) 2014-08-15 2017-08-31 Кариофарм Терапевтикс, Инк. Полиморфы селинексора
CN105439914B (zh) * 2014-09-17 2017-07-11 复旦大学 4‑氨酰基苯氧乙酰胺类化合物及其药物用途
KR101829290B1 (ko) * 2014-12-24 2018-02-19 주식회사 엘지화학 Gpr120 효능제로서의 바이아릴 유도체
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CR20180443A (es) 2016-03-17 2018-11-21 Hoffmann La Roche Derivado de morfolina
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR112022000185A2 (pt) 2019-07-10 2022-02-22 Bayer Ag Método de preparação de 2-(fenilimino)-1,3-tiazolidin-4-onas
JP2024505261A (ja) 2021-01-29 2024-02-05 セディラ・セラピューティクス・インコーポレイテッド Ｃｄｋ２阻害剤およびその使用方法
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338804A1 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
AU783403B2 (en) * 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
KR20040047935A (ko) * 2001-10-25 2004-06-05 쉐링 코포레이션 비만 치료용 ｍｃｈ 길항제

Also Published As

Publication number Publication date
DE10250743A1 (de) 2004-05-19
CN1708476A (zh) 2005-12-14
EA009040B1 (ru) 2007-10-26
EA200500596A1 (ru) 2005-12-29
CA2504207C (en) 2012-10-02
HRP20050383A2 (en) 2006-08-31
PE20040785A1 (es) 2004-12-23
EP1558567A1 (de) 2005-08-03
AU2003285306A1 (en) 2004-05-25
ECSP055765A (es) 2005-07-06
BR0315797A (pt) 2005-09-13
WO2004039764A1 (de) 2004-05-13
ZA200501164B (en) 2006-10-25
DE50311640D1 (de) 2009-08-06
ES2327329T3 (es) 2009-10-28
PL376256A1 (en) 2005-12-27
NO20050745L (no) 2005-05-23
EP1558567B1 (de) 2009-06-24
TW200412936A (en) 2004-08-01
RS20050330A (en) 2007-12-31
UY28051A1 (es) 2004-05-31
ATE434601T1 (de) 2009-07-15
MXPA05002865A (es) 2005-05-27
CA2504207A1 (en) 2004-05-13
CO5570698A2 (es) 2005-10-31
KR20050065654A (ko) 2005-06-29
JP2006504761A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
AR041735A1 (es) Compuestos de amida con accion antagonista de mch y medicamentos que contienen estos compuestos
AR041734A1 (es) Compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos
AR043046A1 (es) Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que contienen estos compuestos y procedimientos para su preparacion
AR048691A1 (es) Compuestos con estructura de alquino con accion antagonista de mch y medicamentos que contienen estos compuestos
AR057982A1 (es) Compuestos de [hetero) arilo con actividad antagonista de mch y composicion farmaceutica que comprende estos compuestos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR064293A1 (es) Derivados de piridazina, composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades asociadas a la hormona concentradora de melanina:mch.
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR029887A1 (es) Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen
AR045699A1 (es) Derivados de triazolopirimidinas como inhibidores de sintasa quinasa 3 de glucogeno
PE20220961A1 (es) Moduladores de la via de respuesta integrada al estres
AR069543A1 (es) Derivados bis-(sulfonilamino), composiciones farmaceuticas que los contienen y su uso en terapia.
AR043049A1 (es) Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica
AR049110A1 (es) Compuestos terapeuticos: piridina como andamiaje estructural
NO20050164L (no) Nye quinuklidin-amid-derivater
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR034264A1 (es) Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas
AR043056A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion, asi como su empleo como medicamentos
AR050617A1 (es) Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas
AR092348A1 (es) DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
ES2188192T3 (es) Bencimidazoles, su preparacion y su empleo como medicamentos.
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
CL2004000788A1 (es) Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d
AR048254A1 (es) Nuevos compuestos beta-cetoamida con efecto antagonistico de mch y medicamentos que contiene estos compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure